创新药受关税消息冲击，恒瑞医药拿下出海大单

Core Viewpoint - The innovative drug sector experienced significant volatility due to tariff news, with the Hang Seng Pharmaceutical ETF (159892) dropping over 2% [1] Group 1: Market Impact - Major holdings such as MicroPort Medical, MicroPort Robotics, and others led the decline, while companies like 3SBio, Alibaba Health, and Zai Lab also saw notable drops [1] - The recent announcement of an overseas exclusive development and commercialization licensing agreement for Ruilong's Trastuzumab, valued at over $1.1 billion, highlights the growing international collaboration in the innovative drug sector [1] Group 2: Long-term Outlook - Since 2025, there has been a surge in large-scale overseas business development deals in the innovative drug sector, indicating increasing global recognition of China's innovative drug capabilities [1] - Leading companies are actively seeking partnerships with top global pharmaceutical firms to expedite the translation of research outcomes into marketable products [1] - While short-term export prospects may be affected by tariff changes, the long-term outlook remains strong due to technological advancements, a shift away from internal competition in the pharmaceutical industry, and breakthroughs in AI-driven drug development [1]